Miconazole revisited: new evidence of antifungal efficacy from laboratory and clinical trials.

In the past 40 years imidazoles have been used extensively in medicine for their antifungal properties. All members of the azole antifungal family inhibit ergosterol biosynthesis. However, the discovery of an additional fungicidal mode of action for miconazole has drawn renewed attention to this compound. In this article we review recent evidence of mechanistic efficacy, as well as clinical trial results of miconazole in new topical formulations.

[1]  C. W. Bailey,et al.  Epidemiology of Oropharyngeal CandidaColonization and Infection in Patients Receiving Radiation for Head and Neck Cancer , 1999, Journal of Clinical Microbiology.

[2]  P. Vescovi,et al.  In vitro antifungal susceptibility to six antifungal agents of 229 Candida isolates from patients with diabetes mellitus. , 2006, Oral microbiology and immunology.

[3]  K. Coley,et al.  Miconazole‐Induced Fatal Dysrhythmia , 1997, Pharmacotherapy.

[4]  L. Koymans,et al.  P450 inhibitors of use in medical treatment: focus on mechanisms of action. , 1995, Pharmacology & therapeutics.

[5]  J. Sobel,et al.  Guidelines for treatment of candidiasis. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  L. Patton,et al.  A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. , 2001, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[7]  E. Katabira,et al.  Comparative Efficacy of Topical Therapy With a Slow-Release Mucoadhesive Buccal Tablet Containing Miconazole Nitrate Versus Systemic Therapy With Ketoconazole in HIV-Positive Patients With Oropharyngeal Candidiasis , 2004, Journal of acquired immune deficiency syndromes.

[8]  G. Calais,et al.  Comparison of the efficacy and safety of miconazole 50‐mg mucoadhesive buccal tablets with miconazole 500‐mg gel in the treatment of oropharyngeal candidiasis , 2008 .

[9]  S. Abe,et al.  Antifungal drug susceptibility of Cryptococcus neoformans from clinical sources in Nairobi, Kenya , 2007, Mycoses.

[10]  A. Reggiori,et al.  Evaluating diagnosis and treatment of oral and esophageal candidiasis in Ugandan AIDS patients. , 1999, Emerging infectious diseases.

[11]  S. Abe,et al.  The Postantifungal Effect (PAFE) of Itraconazole, in Comparison with Those of Miconazole and Fluconazole, on Candida Species , 2006, Microbiology and immunology.

[12]  L. Samaranayake,et al.  Oral candidal infections and antimycotics. , 2000, Critical reviews in oral biology and medicine : an official publication of the American Association of Oral Biologists.

[13]  J. Quiring,et al.  Topical miconazole nitrate ointment in the treatment of diaper dermatitis complicated by candidiasis. , 2006, Cutis.

[14]  W. Du,et al.  Miconazole Induces Changes in Actin Cytoskeleton prior to Reactive Oxygen Species Induction in Yeast* , 2007, Journal of Biological Chemistry.

[15]  J. Perfect,et al.  Oropharyngeal candidiasis in patients with HIV: suggested guidelines for therapy. , 1999, AIDS research and human retroviruses.

[16]  A. Fothergill.  Miconazole: a historical perspective , 2006, Expert review of anti-infective therapy.

[17]  N. Tsuji,et al.  Endogenous Reactive Oxygen Species Is an Important Mediator of Miconazole Antifungal Effect , 2002, Antimicrobial Agents and Chemotherapy.

[18]  T. Young,et al.  Interventions for the prevention and management of oropharyngeal candidiasis associated with HIV infection in adults and children. , 2010, The Cochrane database of systematic reviews.

[19]  C. Dubray,et al.  Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy male and female subjects. , 2004, British journal of clinical pharmacology.

[20]  S. Vaca,et al.  Susceptibility to 5-fluorocytosine, miconazole and amphotericin B of Candida albicans strains isolated from the throat of non-AIDS patients. , 2002, Revista latinoamericana de microbiologia.

[21]  P A Janssen,et al.  Saperconazole: A selective inhibitor of the cytochrome P‐450‐dependent ergosterol synthesis in Candida albicans, Aspergillus fumigatus and Trichophyton mentagrophytes , 1990, Mycoses.

[22]  R. Grimes,et al.  Oral Manifestations of HIV Infection , 1996, Annals of Internal Medicine.

[23]  M. Ghannoum,et al.  Antifungal Agents: Mode of Action, Mechanisms of Resistance, and Correlation of These Mechanisms with Bacterial Resistance , 1999, Clinical Microbiology Reviews.

[24]  H. Devlieger,et al.  Oral Thrush in Children Treated with Miconazole Gel Die Behandlung der oralen Candidose bei Kindern mit Miconazol‐Gel , 1980, Mykosen.

[25]  M. Bonnaure-Mallet,et al.  Oral pathoses caused by Candida albicans during chemotherapy: update on development mechanisms. , 1996, Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics.

[26]  Y. Igarashi,et al.  Feasibility of using collagen as the base of the antifungal drug, miconazole. , 2006, Journal of oral rehabilitation.

[27]  J. Sobel,et al.  Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[28]  J. Pascussi,et al.  Ketoconazole and Miconazole Are Antagonists of the Human Glucocorticoid Receptor: Consequences on the Expression and Function of the Constitutive Androstane Receptor and the Pregnane X Receptor , 2006, Molecular Pharmacology.